Proton pump inhibitors – lansoprazole
Last updated on October 6, 2022
|
Generic name |
lansoprazole |
|
|---|---|---|
|
Strength |
15 mg, 30 mg |
|
| Form |
capsule and rapid dissolve tablet |
|
|
Criteria |
Approval period |
|---|---|
|
1. For gastroesophageal reflux disease (GERD), reflux esophagitis, duodenal ulcer, or gastric ulcer; |
Indefinite |
|
OR 2. For Barrett's esophagus, Zollinger-Ellison syndrome, connective tissue disease, e.g., lupus, scleroderma, CREST; |
Indefinite |
|
OR 3. For eradication of Helicobacter pylori, as part of triple therapy. |
14 days |
|
PLUS Failure of reasonable trials of, or intolerance to, rabeprazole AND pantoprazole magnesium. |
Practitioner exemptions
- No practitioner exemptions.
Special notes
-
CREST is an acronym for the five main features of the limited form of scleroderma: Calcinosis, Raynaud’s disease, Esophageal dysmotility, Sclerodactyly, and Telangiectasia.
-
A reasonable trial of rabeprazole and pantoprazole magnesium is considered a trial at usual adult doses for at least 4 weeks each of rabeprazole and pantoprazole magnesium.